Provectus Pharmaceuticals - Message from the CEO - Exciting results for Phase 2 PV-10 for melanoma clinical trial - Patient enrollment completed for Phase 2 clinical trials of PH-10 for both psoriasis and atopic dermatitis (eczema)

We are pleased you are visiting our Provectus Pharmaceuticals Web site. As you will see, our company is engaged in exciting research & development activities. This site is intended to provide a useful introduction into the innovative world of Provectus.

We are a group of dedicated and entrepreneurial scientists and business people, working together for the past 12 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Provectus develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods.

With our dermatology Phase 2 trials completed, the melanoma Phase 2 trial nearly completed, two expanded access ("compassionate use") programs in place and a key Phase 1 trial underway (assessing PV-10 for use against cancers of the liver), there is a lot to be excited about, on both the clinical development and corporate fronts.

One of the highlights of 2009 was the presentation of interim data from our Phase 2 study of PV-10 for metastatic melanoma at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program in May and June, by Dr. Sanjiv S. Agarwala, Principal Investigator from the PV-10 trial's site at St. Luke's Hospital & Health Network in Bethlehem, PA. The abstract, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)", reported that for the first 40 subjects, a 60% objective response rate was achieved with a 75% rate of loco-regional control of treated lesions. As observed in our previous Phase 1 study, a substantial number of these subjects exhibited evidence of a bystander effect, where it appears that PV-10 ablation induces the subject's immune system to fight untreated tumors elsewhere in the body.

At the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study, reported that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to those of the Phase 1 trial, where markedly longer overall and disease specific survival were observed for subjects that were responsive to PV-10 relative to those who did not experience a robust response.

Based upon requests from physicians, we initiated two expanded access programs ("compassionate use”) for PV-10 in Australia and the U.S. These are active at five of our Phase 2 study centers. As of the end of 2009, a total of 20 melanoma patients, 8 of whom have crossed over from the Phase 2 study to receive further treatment, have commenced treatment with PV-10 under the program. A majority of these patients are in long-term follow-up for up to two years.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis and atopic dermatitis (including atopic eczema). Positive preliminary results from our Phase 2 studies of PH-10 in psoriasis and atopic dermatitis were announced in 2009, illustrating the drug's potential effectiveness as a treatment for serious dermatological diseases and providing compelling data to attract licensure agreements. For psoriasis, preliminary data show that 79% of 29 subjects in the trial demonstrated improvement in the Psoriasis Severity Index (PSI) during four weeks of daily treatment with PH-10. In addition, 83% of subjects reported no or only mild pruritus (itching) by week four of the trial. For atopic dermatitis ("eczema"), preliminary data from the first 18 subjects indicated that 94% had improvement in Eczema Area Severity Index (EASI) scores during four weeks of treatment. In both studies the treatments were generally well tolerated with no significant safety issues identified.

We are proud of our intellectual capital at Provectus. We hold a growing number of U.S. patents in the pharmaceutical, medical device and biotech fields, with many additional patent applications in the works in the U.S. and internationally.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.

Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals